Immutep Limited

Immutep Limited is a clinical-stage biotechnology company headquartered in Sydney, Australia, with operations also in Germany, France, and the United States. The company is a global leader and pioneer in the development of novel immunotherapies for cancer and autoimmune diseases, specifically focusing on therapeutics related to Lymphocyte Activation Gene-3 (LAG-3). Its mission is to leverage immunotherapy to develop safe, innovative treatment options for patients and to maximize shareholder value through disciplined and accurate research.

Immutep's diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. The lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3Ig fusion protein designed as an antigen-presenting cell (APC) activator for various cancer treatments. Other key candidates include IMP761, a LAG-3 agonist antibody for autoimmune diseases, and IMP731, a depleting LAG-3 antibody for autoimmune conditions, which has been licensed to GlaxoSmithKline. Additionally, LAG525, an antagonist antibody targeting LAG-3 for cancer treatment, is out-licensed to Novartis.

In March 2026, Immutep discontinued its Phase III TACTI-004 trial in first-line non-small cell lung cancer (NSCLC) following a futility analysis, which led to a significant stock decline. Despite this setback, other efti programs are ongoing, including encouraging data from INSIGHT-003 in lung cancer, the EFTISARC-NEO soft tissue sarcoma trial meeting its primary objective, and continued follow-up for AIPAC-003 in metastatic breast cancer. The Phase I study for IMP761 in autoimmune diseases has shown favorable safety data and is progressing. Efti also received FDA orphan drug designation for soft tissue sarcoma in April 2026. Marc Voigt serves as the CEO, and Dr. Frédéric Triebel, the discoverer of LAG-3, is the Chief Scientific and Medical Officer. The company reported a cash position of A$110.6 million as of March 31, 2026, with an expected cash runway into the first half of calendar year 2028.